Kotak Mutual Fund raised its stake in IPCA Laboratories from 6.36% to 7.42%, purchasing 26,75,309 shares.
A pharmaceutical manufacturer and marketer, Ipca Labs produces a wide range of medicines across therapeutic areas including antimalarials, anti-infectives, gastrointestinal treatments, and gynecological formulations. The company operates manufacturing facilities across India and exports its products to international markets. Its distinctive strength lies in its expertise in complex drug formulations, established distribution networks across Indian states, and a focus on affordable healthcare solutions for domestic and global markets.
Wholly owned subsidiary of Kotak Mahindra Bank, one of India's leading private banks. Manages over Rs 4.5 lakh crore in AUM. MD Nilesh Shah is a fixture in Indian financial media and one of the most quoted fund managers in the country. Known for disciplined quality growth positioning and clear communication of investment rationale to investors.
